Ovarian Cancer

A medical expert navigates clinical pathway considerations in the treatment of ovarian cancer.

Emily Graham, PharmD, MS, BCOP, an Oncology Clinical Pharmacy Specialist at Allegheny Health Network in Pittsburg, Pennsylvania, discusses the potential outcomes of mirvetuximab for patients with platinum-resistant ovarian cancer.

Frequent aspirin use associated with a 13% lower risk of nonmucinous ovarian cancer, which was consistent with findings from previous studies.

Quality of life and safety profiles are discussed by Ryan Haumschild, PharmD, MS, MBA.

Dr Haumschild navigates financial considerations associated with treatment of ovarian cancer.

Dr Haumschild discusses the substantial impact of clinical pathways in the treatment of ovarian cancer.

The significance of multidisciplinary teams in ovarian cancer treatment is highlighted.

Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.

Dr Haumschild explores considerations for safe and appropriate dosing for patients receiving PARP inhibitor therapy.

PARP inhibitors in particular have changed the therapeutic landscape for EOC.

Numerous clinical trials are investigating the next generation of PARPi.

Ultra-processed food consumption linked to an increased risk of developing and dying from ovarian cancer and breast cancer.

Patients who received the interventions reported improved anxiety and pain levels.

Mirvetuximab soravtansine-gynx (Elahere; ImmunoGen Inc) approved FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.

AstraZeneca’s Lynparza in combination or as a monotherapy demonstrates meaningful survival benefit in long-term follow-up.

Research suggests that rucaparib can increase progression-free survival by more than a year in women with advanced ovarian cancer.

New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.

Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.

Rucaparib (Rubraca) is a poly (ADP-ribose) polymerase (PARP) inhibitor used for ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and castration-resistant prostate cancer.

Folate receptor α may be an important treatment target for ovarian tumors.

In clinical trials, dabrafenib and trametinib showed meaningful efficacy in multiple BRAF-positive tumor types, including in patients with rare cancers who have no other treatment options available.

Rucaparib at the 400 mg dosage combined with nivolumab and ipilimumab for 4 cycles will continue onto a phase 2 trial for individuals with relapsed ovarian cancer.